Many Quebecers have been victimized by the rampant prescription of opioids as a result of the misleading and aggressive sales and marketing efforts of numerous pharmaceutical companies.

On May 23, 2019, Fishman Flanz Meland Paquin LLP, in collaboration with Trudel, Johnston & Lespérance, filed an application for authorization to institute a class action against the manufacturers, marketers and/or distributors of opioid drugs in Quebec, including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and oxymorphone (the “Quebec Opioid Class Action”).

The Quebec Opioid Class Action seeks to compensate every person in Quebec who suffers or has suffered from opioid use disorder following the use of prescription opioids and who has been diagnosed by a physician with opioid use disorder.

The Quebec Opioid Class Action was authorized by judgment dated April 10, 2024 of the Superior Court of Quebec (Class Action Chamber).

Since the Quebec Opioid Class Action was instituted, a number of settlements were reached with defendants and the decision was made to make a distribution to eligible class members even though the action is still ongoing against the remaining defendants. On December 22, 2025, the Court approved the distribution protocol/the claims process and appointed MNP Ltd. as the claims administrator. The amount to distribute exceeds $20 million.

For more information about the claims process and to fill out a claim form, please visit MNP’s website: Quebec Opioid Class Action.